Investing.com — Dyne Therapeutics, a biotechnology firm, noticed its shares rise by as much as 10% after the market closed on Wednesday.
The surge in inventory value got here as the corporate introduced an investor convention name to overview new medical information.
The info is from its ACHIEVE trial, a examine specializing in a but undisclosed remedy. The corporate has not supplied additional particulars on the character of the trial or the info to be reviewed.
Dyne Therapeutics, which makes a speciality of creating therapies for sufferers with critical muscle illnesses, mentioned the overview of the info is scheduled for January 10.
This text was generated with the assist of AI and reviewed by an editor. For extra data see our T&C.
A single ticket-holder might win the largest lottery prize the UK has ever seen in…
Elon Musk posted in February that he liked his president, patron and private buddy, "as…
The US economic system noticed a slowdown in hiring however no leap in unemployment final…
Directors are on standby to deal with the collapse of the UK arm of Builder.ai,…
The proprietor of SlimFast has kicked off a sale of the burden loss model after…
A former McKinsey boss is among the many candidates being thought-about to interchange Sir Mark…